News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Ophthalmology Futures European Forum Presentation

News Releases

Date Title and Summary Additional Formats
Toggle Summary Aerie Pharmaceuticals to Present at Ophthalmology Futures Forums in Vienna, Austria
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Appoints David W. Gryska to the Company’s Board of Directors
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 12, 2018-- Aerie Pharmaceuticals, Inc.  (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Robert Finan as Director of Finance
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 11, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Thomas A. Shepard as Vice President, Implant Manufacturing
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 10, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other
View HTML